DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR GLASDEGIB
All Clinical Trials for Glasdegib
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02226172 | Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib | Recruiting | Pfizer | Phase 2 | 2014-10-01 | A lead-in cohort of ~20 patients with primary or secondary myelofibrosis previously treated with 1 or more Janus kinase inhibitors enrolled to single-agent glasdegib to evaluate safety and tolerability. Following the lead-in, a phase 2, double blind, 2-arm study, randomized 2:1 to oral single-agent glasdegib versus placebo in 201 patients resistant or intolerant to ruxolitinib. |
| NCT02367456 | A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In 1st Line MDS, AML and CMML Patients | Recruiting | Pfizer | Phase 1 | 2015-04-01 | This multi center randomized (1:1), double blind, placebo controlled Phase 1b/2 study is designed to compare the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of PF 04449913 or placebo when combined with azacitidine in patients with previously untreated Intermediate 2 or High Risk Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML) with 20-30% blasts and multi lineage dysplasia, and Chronic Myelomonocytic Leukemia (CMML). This clinical study includes two components: (a) a Phase 1b safety lead in and (b) a randomized Phase 2. |
| NCT02430545 | Understanding The Effect Of A Strong CYP3A4 Inducer On Glasdegib Pharmacokinetics | Completed | Pfizer | Phase 1 | 2015-05-01 | The study also aims to determine the effect of a strong enzyme (CYP3A4) inducer-rifampin- on drug exposure of Glasdegib. This study will be conducted in healthy subjects given a single dose of glasdegib in each period. |
| NCT03130556 | A Study Of Glasdegib In Healthy Volunteers To Establish The Bioequivalence Of The Phase 2 Formulation To The ICH Formulation | Recruiting | Pfizer | Phase 1 | 2017-05-01 | This study is intended to establish the bioequivalence (BE) of single 100 mg doses of glasdegib administered under fasted conditions to healthy volunteers as the ICH formulation compared to the Phase 2 formulation. |
| NCT03162900 | A Phase 1 Study To Evaluate The Effect Of Glasdegib On The Cardiac Repolarization In Healthy Subjects | Not yet recruiting | Pfizer | Phase 1 | 2017-06-27 | This is a Thorough QT study intended to estimate the effect of glasdegib at therapeutic exposure and at supra-therapeutic exposure on cardiac repolarization in healthy subjects. This is a randomized, double blind, positive and placebo controlled study with a 6 day washout between successive periods. |
| NCT03270878 | Glasdegib Absolute Bioavailability Study | Not yet recruiting | Pfizer | Phase 1 | 2017-09-05 | This study is intended to estimate the absolute bioavailability of Glasdegib by comparison of the pharmacokinetic exposures following administration of an oral, single dose 100 mg tablet vs. an IV infusion of a 50 mg IV dose in the fasted state in a crossover fashion to healthy volunteers. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Glasdegib
Condition Name
Condition MeSH
Clinical Trial Locations for Glasdegib
Trials by Country
Clinical Trial Progress for Glasdegib
Clinical Trial Phase
Clinical Trial Sponsors for Glasdegib
Sponsor Name
